ADC Therapeutics Stock

adctherapeutics.comHealthcareFunding to Date: $200.02MM

ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.

Register for Details

For more details on financing and valuation for ADC Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for ADC Therapeutics.

Register Today


Management Team

Susan Romanus
Chief Compliance Officer
St├ęphane Henchoz
Director, Finance
David Ellis Ph.D
Head of Global Regulatory Affairs
Patrick Van Berkel Ph.D
Senior Vice President, Research & Development
Michael Forer
Vice Chairman, Executive Vice President & Chief Financial Officer
Maria Cincotta
Head of Global Clinical Science and Operations
Jay Feingold Ph.D
Chief Medical Officer, Senior Vice President Head of Oncology Clinical Development
Richard Warburg Ph.D
Head, Intellectual Property
Chris Martin Ph.D
Chief Executive Officer & Board Member
Michael Mulkerrin Ph.D
Head of Chemistry Manufacturing and Control & Vice President
Esohe Idusogie Ph.D
Head of Process Quality and CMC Analytical
Richard Onyett
Vice President, Business Development

Board Members

Chris Martin Ph.D
Jacques Theurillat
Peter Corr Ph.D
Auven Therapeutics
Thomas Pfisterer
Wild Family Office
Barrie Ward Ph.D
Stephen Evans-Freke
Auven Therapeutics
Tyrell Rivers Ph.D
Peter Hug Ph.D
Thomas Rinderknecht Ph.D

Other companies like ADC Therapeutics in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation